Drug trial results refine treatment during angioplasty ... ( A landmark international study coord...)

Drug trial results refine treatment during angioplasty operations

Date:8/31/2010

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

In a prior study, the OASIS 5 trial, researchers from McMaster University showed that a blood thinner fondaparinux compared to another blood thinner, enoxaparin, reduced serious bleeding and prevented deaths in patients with heart attacks. A limitation of this new agent, fondaparinux, was its higher rates of clot formation in equipment during angioplasty. As a result, an additional blood thinner UFH had been recommended during angioplasty to prevent clotting in those who had received fondaparinux, but there was uncertainty about the optimal dose.

Even though UFH has been used during angioplasty since the procedure was first performed, little is known about the optimal dose of the agent.

An international group of researchers from 18 countries found patients undergoing angioplasty did not benefit from a lower dose of UFH compared to a standard dose in those on fondaparinux.

Importantly, the addition of either low or standard dose UFH to fondaparinux did not increase serious bleeding and prevented clot formation in equipment during angioplasty when compared to patients treated with fondaparinux alone in OASIS 5. As a result, adding standard dose UFH to fondaparinux maintains the major advantage of fondaparinux (lower bleeding) while preventing clotting during the angioplasty procedure.

"Our data clearly shows that adding UFH to fondaparinux maintains a low rate of major bleeding and prevents catheter thrombosis," said interventional cardiologist Dr. Sanjit Jolly, an assistant professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University.

Dr. Jolly is scheduled to prese
'/>"/>

Contact: Laura Thompson
lthomp@mcmaster.ca
905-525-9140
McMaster University
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Success stops drug trial
2. In Early Trial, Targeted Therapy Fights Advanced Melanoma
3. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
4. Decade-long trial confirms benefts of steroid withdrawal for transplant patients
5. Trial Therapy Improves Melanoma Survival
6. CRF announces featured clinical trials to be presented at TCT 2010
7. Clinical trials: Comprehension unaffected by simplified consent forms or payment
8. Clinical trials abroad: Making non-English language consent forms readable
9. Human clinical trial of NIH-developed dengue vaccine begins
10. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
11. Drug trials funded by industry are more likely to publish favorable results

Post Your Comments:

(Date:5/22/2012)... Philadelphia, Pa. (May 22, 2012) Potentially severe hypersensitivity ... autoimmune mechanism, resulting from the creation of drug-induced immunogens ... to a study published online by the journal ... International AIDS Society . AIDS is published ... of Wolters Kluwer Health . , The study ...

(Date:5/22/2012)... weight-loss products are the types of dietary supplements most ... new study. Liver injury from medication is the ... and herbal supplements -- which do not require a ... online -- are used by up to 40 percent ... side effects are not well-known. In this study, ...

(Date:5/22/2012)... (HealthDay News) -- New Mexico has the highest rate ... Jersey has the lowest rate, according to a new ... 100,000 people, while New Jersey,s is about 36 per ... about 58 per 100,000, according to the report released ... Wood Johnson Foundation. Injuries that result from accidents, ...

(Date:5/22/2012)... When thousands of psychiatrists attend their field,s largest annual ... into drug treatments report overwhelmingly on positive results. ... in the Journal of Clinical Psychopharmacology by ... Yale University, who analyzed the presentations given at two ... Of 278 studies presented at the 2009 and 2010 ...

(Date:5/22/2012)... ANTONIO (May 22, 2012) An international task force ... distress syndrome (ARDS), a disease first recognized during the ... trouble breathing. , The new definition includes a distinction ... that are less advanced, said Antonio Anzueto, M.D., of ... the ARDS Definition Task Force. The guidelines are based ...

Breaking Medicine News(10 mins):Health News:Reactions to HIV drug have autoimmune cause, reports AIDS journal 2 Health News:Reactions to HIV drug have autoimmune cause, reports AIDS journal 3 Health News:Body Building, Diet Supplements Linked to Liver Damage: Study 2 Health News:Injury-Linked Deaths Vary Widely Among States 2 Health News:Bias found in mental health drug research presented at major psychiatric meeting 2 Health News:Bias found in mental health drug research presented at major psychiatric meeting 3 Health News:Revised ARDS definition sets out levels of severity 2

[0] Reactions to HIV drug have autoimmune cause, reports AIDS journal [0] Body Building, Diet Supplements Linked to Liver Damage: Study [0] Injury-Linked Deaths Vary Widely Among States [0] Bias found in mental health drug research presented at major psychiatric meeting [0] Revised ARDS definition sets out levels of severity

... Will Teach an Innovative Educational Event on the Web....,Four part web-based ... then will be available on every major social networking site afterwards ... ... Integrative medicine pioneer, renowned psychiatrist and educator, James S. Gordon, M.D., ...

... Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ), ... cosmetic treatments, today announced financial,results for the third ... ended September 30, 2008 were $24.2 million, of ... royalty revenues, $1.0 million,were funded development revenues, and ...

... Suggests Hospitals Increasingly use IROS to address the Joint ... ... Healthcare Management,announced today the results of its annual Hospital Peer ... U.S. hospital professionals on their use of AllMed,s external,peer review ...

... to Eat Right, Move More and ... Milk Their Diets, ATLANTA, Oct. ... different fad diets -- which seem to go in and out of,fashion like ... Americans -- including 56 percent of Georgia,residents -- remain overweight or obese., ...

... 30 Triple-S,Management Corporation (NYSE: GTS ), the ... consolidated revenues for the three,months ended September 30, 2008. ... includes an after tax net loss of $5.4 million, ... losses on investments and,derivatives. Also, the Company,s Board of ...

... Inc. (Nasdaq: MBRK ), a pharmaceutical company ... scheduled,to announce its financial results for the third ... the market opens. At 9:00 a.m. (ET) on ... to review the,Company,s third quarter financial results., ...

Integrative Medicine Pioneer To Host Free Groundbreaking Web Series on a Natural Approach for Treating Depression Palomar Medical Reports Financial Results for Third Quarter 2008 AllMed Announces Annual Hospital Peer Review Survey Results Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results

(Date:5/22/2012)... Calif. and BELGRADE, Serbia, May 22, 2012 /PRNewswire/ ... therapies for cardiovascular and renal diseases, presented positive ... CLP1001. In the study of 111 heart failure ... in heart failure symptoms as compared to placebo. ... Phase 2a study were presented in an oral ...

(Date:5/22/2012)... GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical ... Immunodeficiency Virus (HIV) infections, today announced that the ... enrollment for a Phase 1 trial for the ... identical to the first generation (currently ... the inclusion of granulocyte-macrophage colony-stimulating factor (GM-CSF) as ...

(Date:5/22/2012)... May 22, 2012 USANA Health Sciences , ... supplement company, today announced the promotion of Dr. John ... and Dr. Brian Dixon to executive director of new ... licensed naturopathic physician, Mark Levy, a Ph.D. in human ... trainer and adjunct professor at the University of Utah, ...

Breaking Medicine Technology:Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2 Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3 HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 2 HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 3 HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 4 USANA Health Sciences Expands Award-Winning Research and Development Team 2 USANA Health Sciences Expands Award-Winning Research and Development Team 3 Nanocrystal doping developed by Hebrew University researchers enhances semiconductor nanocrystals 19050 1 Nanocrystal doping developed by Hebrew University researchers enhances semiconductor nanocrystals 19050 2 delSECUR CORPORATION Announces Its Dissolution 3B and the Distribution of Its Asset to Its Lenders and Shareholders of the Corporation 19046 1 delSECUR CORPORATION Announces Its Dissolution 3B and the Distribution of Its Asset to Its Lenders and Shareholders of the Corporation 19046 2 Mangroves among the most carbon rich forests in the tropics 18636 1 Mangroves among the most carbon rich forests in the tropics 18636 2

[0] Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study [0] HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine [0] USANA Health Sciences Expands Award-Winning Research and Development Team

... CHKT, VANCOUVER, April 02, 2007 /PRNewswire-FirstCall/ - ... company,developing chemokine-based therapies to treat cancer, blood,disorders, ... of Texas M. D. Anderson Cancer Center's ... with a CXCR4,antagonist in a mouse model ...

... 2007 - Opexa,Therapeutics, Inc. (NASDAQ: OPXA), a ... cell therapies, today,announced positive top-line data in ... of the investigational T-cell vaccine,Tovaxin(TM), for multiple ... trial, Tovaxin therapy was shown to be,safe ...

Other Medicine Technology:M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 2 M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 3 M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 4 Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis 2 Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis 3 Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis 4

M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...

... Carl Zeiss is expanding the borders ... field, excellent color reproduction, high-contrast images ... patented optics provide improved resolution and ... (Systems Control Panel) combines all essential ...

Compact tray features all components for urethral catheterization....

Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....

Medicine Products:

Finnpipette Fixed Volume, 3000ul SteREO Discovery. V12 CURITY Urethral Catheter Tray (Open)Advance Plus Intermittent Catheter (Kit)

Drug trial results refine treatment during angioplasty ...( A landmark international study coord...),Health